AI English summary of an SEC filing — figures as filed
Vertex Pharmaceuticals VRTXVertex said full-year 2024 product revenue was $11.02 billion, up 12% from 2023. The company cited continued performance of TRIKAFTA/KAFTRIO as the main driver. U.S. net product revenue was $6.68 billion (up 11%), and net product revenue outside the U.S. was $4.34 billion (up 13%).
Key points
AI summaryVertex said full-year 2024 product revenue was $11.02 billion, up 12% from 2023. The company cited continued performance of TRIKAFTA/KAFTRIO as the main driver. U.S. net product revenue was $6.68 billion (up 11%), and net product revenue outside the U.S. was $4.34 billion (up 13%).
Vertex said it reported a GAAP net loss of $(536) million and Non-GAAP net income of $111 million for full-year 2024, compared with net income of $3.6 billion and $4.0 billion, respectively, for 2023. The company cited acquired IPR&D expense of $4.4 billion related to its Alpine acquisition.
Vertex issued full-year 2025 total revenue guidance of $11.75 billion to $12.0 billion. It also guided to combined Non-GAAP R&D, AIPR&D and SG&A expenses of $4.9 billion to $5.0 billion and a Non-GAAP effective tax rate of 20.5% to 21.5%.
Vertex said it announced on February 10, 2025 that Stuart A. Arbuckle will retire as Chief Operating Officer, effective July 1, 2025. It also announced the appointment of Charles F. Wagner, Jr. as Chief Operating Officer and Duncan J. McKechnie as Chief Commercial Officer. Wagner will remain Chief Financial Officer and entered into a new employment agreement with a base salary of $1,000,000 and a target annual bonus of 100%.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.
Vertex reports full-year 2024 product revenue of $11.02 billion
Vertex said full-year 2024 product revenue was $11.02 billion, up 12% from 2023. The company cited continued performance of TRIKAFTA/KAFTRIO as the main driver. U.S. net product revenue was $6.68 billion (up 11%), and net product revenue outside the U.S. was $4.34 billion (up 13%).
Source · Based on the filing body and exhibits
Vertex reports 2024 GAAP net loss of $(536) million
Vertex said it reported a GAAP net loss of $(536) million and Non-GAAP net income of $111 million for full-year 2024, compared with net income of $3.6 billion and $4.0 billion, respectively, for 2023. The company cited acquired IPR&D expense of $4.4 billion related to its Alpine acquisition.
Source · Based on the filing body and exhibits
Vertex issues full-year 2025 guidance
Vertex issued full-year 2025 total revenue guidance of $11.75 billion to $12.0 billion. It also guided to combined Non-GAAP R&D, AIPR&D and SG&A expenses of $4.9 billion to $5.0 billion and a Non-GAAP effective tax rate of 20.5% to 21.5%.
Source · Based on the filing body and exhibits
Executive changes and Charles F. Wagner, Jr. agreements
Vertex said it announced on February 10, 2025 that Stuart A. Arbuckle will retire as Chief Operating Officer, effective July 1, 2025. It also announced the appointment of Charles F. Wagner, Jr. as Chief Operating Officer and Duncan J. McKechnie as Chief Commercial Officer. Wagner will remain Chief Financial Officer and entered into a new employment agreement with a base salary of $1,000,000 and a target annual bonus of 100%.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…